BEGIN:VCALENDAR VERSION:2.0 PRODID:-//jEvents 2.0 for Joomla//EN CALSCALE:GREGORIAN METHOD:PUBLISH BEGIN:VEVENT UID:68d676bf20b04556d28bf595a2e4bccf CATEGORIES:Colloquium CREATED:20220119T155615 SUMMARY:Professor Jun Wang, Ernest Mario School of Pharmacy, Rutgers University DESCRIPTION:Medicinal Chemistry and Pharmacology of Antivirals Targeting SARS-CoV-2\nMy lab is interested in developing antivirals targeting emerging and re-emerg ing viruses, including influenza A and B viruses, enterovirus D68 (EV-D68), EV-A71, coxsackievirus, poliovirus, and the coronaviruses such as SARS-CoV -2. The central themes are the identification of new drug targets and the development of novel small molecules for use as chemical probes for target validation as well as drug candidates for translational research. \nIn this talk, I will introduce our efforts in developing antivirals targeting SARS -CoV-2 main protease (Mpro or 3CLpro) and papain-like protease. Mpro and PL Pro are involved in the cleavage the viral polyproteins during the viral re plication and are validated antiviral drug targets. In addition, PLpro has been shown to modulate host immune response. Through high-throughput screen ing and structure-based drug design, we have discovered covalent and non-co valent Mpro and PLpro inhibitors with potent enzymatic inhibition and cellu lar antiviral activity against SARS-CoV-2. In addition, we have solved mult iple X-ray co-crystal structures of Mpro and PLpro with inhibitors. The tal k will focus on target selectivity, new cysteine reactive warheads, assay d evelopment, and pharmacology of Mpro and PLpro inhibitors. \nHosted by Pro fessor Zheng Shi\nFor Zoom meeting information, please contact Loretta Lupo @ (mailto:lal275@chem.rutgers.edu)This email address is being protected f rom spambots. You need JavaScript enabled to view it.\n X-ALT-DESC;FMTTYPE=text/html:
Medicinal Chemistry and Pharmacology of Antivirals Targe ting SARS-CoV-2
My lab is inter ested in developing antivirals targeting emerging and re-emerging viruses, including influenza A and B viruses, enterovirus D68 (EV-D68), EV-A71, coxs ackievirus, poliovirus, and the coronaviruses such as SARS-CoV-2. The centr al themes are the identification of new drug targets and the developm ent of novel small molecules for use as chemical probes for target validati on as well as drug candidates for translational research.
In this talk, I will introduce our efforts in devel oping antivirals targeting SARS-CoV-2 main protease (Mpro or 3CLpro) and pa pain-like protease. Mpro and PLPro are involved in the cleavage the viral p olyproteins during the viral replication and are validated antiviral drug t argets. In addition, PLpro has been shown to modulate host immune response. Through high-throughput screening and structure-based drug design, we have discovered covalent and non-covalent Mpro and PLpro inhibitors with potent enzymatic inhibition and cellular antiviral activity against SARS-CoV-2. I n addition, we have solved multiple X-ray co-crystal structures of Mpro and PLpro with inhibitors. The talk will focus on target selectivity, new cyst eine reactive warheads, assay development, and pharmacology of Mpro and PLp ro inhibitors.
Hosted by Professor Zheng Shi
For Zoom me
eting information, please contact Loretta Lupo @